The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Matthew Galsky
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; EMD Serono; Gilead Sciences; Janssen; Merck; Pfizer
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - METHODS AND COMPOSITIONS FOR TREATING CANCER AND RELATED METHODS. MOUNT SINAI SCHOOL OF MEDICINE July 2012 Application number: 20120322792
 
Joaquim Bellmunt
Stock and Other Ownership Interests - Rainier Therapeutics
Honoraria - UpToDate
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; EMD Serono/Merck; Merck; Novartis; Pfizer; Pierre Fabre
Research Funding - Pfizer/EMD Serono (Inst); Pfizer/Gilead
Patents, Royalties, Other Intellectual Property - UpToDate Bladder Cancer
Travel, Accommodations, Expenses - Genentech/Roche; Ipsen
 
Charlene Mantia
Consulting or Advisory Role - AADi; Cogent Biosciences; EMD Serono; Nextech; Synthekine
Research Funding - Bristol-Myers Squibb (Inst)
 
Benjamin Garmezy
Consulting or Advisory Role - Abbvie (Inst); Adaptimmune (Inst); Adicent Therapeutics (Inst); AIQ Global (Inst); Amgen (Inst); Arcus Biosciences (Inst); Arvinas (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); EMD Serono (Inst); Exelixis (Inst); Genentech/Roche (Inst); Janssen (Inst); Merck (Inst); Monte Rosa Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Rondo Therapeutics (Inst); Seagen (Inst); Specialty Networks (Inst); Takeda (Inst); Xencor (Inst)
Research Funding - Abbvie (Inst); Accutar Biotech (Inst); Adcentrx Therapeutics (Inst); Adicet Therapeutics (Inst); Amgen (Inst); Arcus Biosciences (Inst); Arvinas (Inst); AstraZeneca (Inst); Avenzo Therapeutics (Inst); AVEO (Inst); Bicycle Therapeutics (Inst); crispr therapeutics (Inst); Eikon Therapuetics (Inst); Envision Pharma Group (Inst); Exelixis (Inst); Flare Therapeutics (Inst); Halda Therapeutics (Inst); Harbour BioMed (Inst); HiberCell (Inst); IDEAYA Biosciences (Inst); Janssen Oncology (Inst); Janux Therapeutics (Inst); Jubilant Therapeutics (Inst); Kineta (Inst); Kinnate Biopharma (Inst); Loxo (Inst); Merck (Inst); MiNK Therapeutics (Inst); Novartis (Inst); Nuvation Bio (Inst); Pfizer (Inst); ProfoundBio (Inst); Roche/Genentech (Inst); Takeda (Inst); Teon Therapeutics (Inst); Tmunity Therapeutics, Inc. (Inst); Xencor (Inst); Zenshine (Inst)
 
Gopa Iyer
Consulting or Advisory Role - AstraZeneca; Biohaven Pharmaceuticals; EMD Serono; Flare Therapeutics; Janssen; Loxo/Lilly; Mirati Therapeutics
Research Funding - AADi (Inst); Flare Therapeutics (Inst); Janssen (Inst); Loxo/Lilly (Inst); Pfizer (Inst)
Other Relationship - DAVA Oncology
 
Daniel Petrylak
Consulting or Advisory Role - Advanced Accelerator Applications; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bicycle Therapeutics; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Exelixis; Gilead Sciences; Incyte; Ipsen; Janssen; Lilly; Mirati Therapeutics; Monopteros Therapeutics; Pfizer; Pharmacyclics; Regeneron; Roche; Seagen; Urogen pharma
Research Funding - Advanced Accelerator Applications (Inst); Agensys (Inst); Astellas Medivation (Inst); AstraZeneca (Inst); Bayer (Inst); BioXCel therapeutics (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Eisai (Inst); Endocyte (Inst); Genentech (Inst); Gilead Sciences (Inst); Innocrin Pharma (Inst); Lilly (Inst); MedImmune (Inst); Medivation (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Progenics (Inst); Replimune (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst)
Expert Testimony - Celgene; sanofi
 
Evisa Gjini
Employment - Flare Therapeutics; Takeda (I)
Stock and Other Ownership Interests - Takeda (I)
Travel, Accommodations, Expenses - Takeda (I)
 
Adarsh Joshi
Employment - Flare Therapeutics
Stock and Other Ownership Interests - Flare Therapeutics (I)
 
Yelena Mikhailov
No Relationships to Disclose
 
Ani Nguyen
Employment - Flare Therapeutics
 
Bijal Kakrecha
Employment - Flare Therapeutics
Stock and Other Ownership Interests - Flare Therapeutics
Travel, Accommodations, Expenses - Flare Therapeutics
 
Michael Meyers
Employment - Flare Therapeutics Inc.; Syndax
Leadership - Flare Therapeutics Inc; Nuvalent Therapeutics; Syndax
Stock and Other Ownership Interests - Auron Therapeutics; Flare Therapeutics Inc; Nuvalent, Inc.; Syndax
Consulting or Advisory Role - Auron Therapeutics; Nuvalent, Inc.; Syndax
Patents, Royalties, Other Intellectual Property - Nuvalent, Inc.; Syndax
 
Michaela Bowden
Employment - Flare Therapeutics
Leadership - Flare Therapeutics
Stock and Other Ownership Interests - Flare Therapeutics
 
Matthew Milowsky
Stock and Other Ownership Interests - Gilead Sciences; Pfizer
Research Funding - Acrivon Therapeutics (Inst); Alliance for Clinical Trials in Oncology (Inst); ALX Oncology (Inst); Amgen (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Flare Therapeutics (Inst); G1 Therapeutics (Inst); Loxo/Lilly (Inst); Merck (Inst); Novartis (Inst); OncoC4 (Inst); PCCTC (Inst); Pfizer (Inst); Roche (Inst)
Other Relationship - Elsevier; OncLive/MJH Life Sciences; Prime Education; Research to Practice
(OPTIONAL) Uncompensated Relationships - G1 Therapeutics; Loxo/Lilly
 
Xin Gao
Consulting or Advisory Role - 858 Therapeutics; Abeona Therapeutics; ADC Therapeutics; Arvinas; Bayer; Flare Therapeutics; Hinova Pharmaceuticals; Janssen; Kanaph Therapeutics; Loxo/Lilly
Research Funding - ALX Oncology (Inst); Aprea Therapeutics (Inst); Aravive (Inst); Arvinas (Inst); Bayer (Inst); Exelixis (Inst); Halda Therapeutics (Inst); Harpoon therapeutics (Inst); Janux Therapeutics (Inst); Loxo/Lilly (Inst); Merck (Inst); Novartis (Inst); Nuvation Bio (Inst); Pfizer (Inst); Poseida therapeutics (Inst); Regeneron (Inst); Takeda (Inst); TopAlliance BioSciences Inc (Inst)